ENO1 and pancreatic neoplasm: Interestingly, GLS inhibition significantly decreased CFPAC-1 survival suggesting that pancreatic cancer cells, known to have specific addiction to glutamine [20], are markedly more sensitive to GLS inhibition when ENO1 function is impaired.